- Investigator
- Jorge E Lascano
- Status
- Accepting Candidates
Accepted insurances
Please note: Some physicians and practices might not accept a specific insurance plan. Our list is also subject to change, and sometimes that change is not yet reflected in this list. Please contact the practice to confirm that your insurance is accepted. A representative will be happy to assist you.
See all insurancesMy locations
Active clinical trials
The REACH study is for people with CF who do not take cystic fibrosis transmembrane conductance regulator (CFTR) modulators. The goal of the REACH study is to collect research data, including health data and specimens, from people with CF who do not…
- Investigator
- Jorge E Lascano
- Status
- Accepting Candidates
- Ages
- 12 Years - N/A
- Sexes
- All
The Sponsor is developing KB408, a replication-defective, non-integrating herpes simplex virus type 1 (HSV-1)-derived vector engineered to deliver functional full-length human SERPINA1 to the airways of people with alpha-1 antitrypsin deficiency…
- Investigator
- Jorge E Lascano
- Status
- Accepting Candidates
- Ages
- 18 Years - 70 Years
- Sexes
- All
My research
Top areas of exploration
- alpha 1-Antitrypsin Deficiency , 10 publications
- Pulmonary Disease, Chronic Obstructive , 9 publications
- alpha 1-Antitrypsin , 7 publications
- Cystic Fibrosis , 4 publications
Research activity
My areas of focus
Stories and news
Eyes on the Prize: Progress in Cystic Fibrosis Research Amidst a Pandemic
Just over one year ago, COVID-19 exploded on news headlines — putting the world in a tizzy about what this new virus was, who was at risk and how to prevent…
Changing the Narrative of Cystic Fibrosis
There was once a time where cystic fibrosis, or CF, was considered a terminal disease. While this may have been the case years ago, patients diagnosed with CF…
